Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13244187 | 0.81 | RAB9A (0.56) | THRATHRBLTB4RALDH1A1RAB9A | |
| SCHEMBL9780857 | 0.80 | KMT2A (0.61) | PYGLLTB4RALDH1A1ALB | |
| SCHEMBL9780778 | 0.78 | KMT2A (0.62) | PYGLLTB4R | |
| SCHEMBL6579131 | 0.78 | PYGL (0.64) | PYGLPLAUTHRATHRBALDH1A1 | |
| SCHEMBL27634252 | 0.77 | KMT2A (0.49) | PYGLLTB4RALDH1A1 | |
| SCHEMBL7706321 | 0.76 | PYGL (0.45) | PYGLPLAUTHRATHRBLTB4R | |
| SCHEMBL13244177 | 0.75 | RAB9A (0.49) | LTB4RRAB9AKDM4ETSHR | |
| SCHEMBL23573822 | 0.75 | CYP3A4 (0.42) | PLAUTHRBALDH1A1LMNATSHR | |
| SCHEMBL5339875 | 0.75 | LMNA (0.49) | PYGLTHRATHRBLTB4RALDH1A1 | |
| SCHEMBL7965637 | 0.74 | PYGL (0.43) | PYGLPLAUTHRATHRBALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1280266-C | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2006-10-18 | — | — | CN | disclosed |
| EP-1294682-B1 | ACYLPHENYL UREA DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2004-04-28 | — | — | EP | disclosed |
| CN-1434796-A | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA GMBH | 2003-08-06 | — | — | CN | disclosed |
| EP-1294682-A1 | ACYLPHENYL UREA DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS A MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-6506778-B2 | Antidiabetic agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-14 | — | — | US | disclosed |
| US-20020151586-A1 | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2001094300-A1 | ACYLPHENYL UREA DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151586-A1 | Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals | ACAD11, CYP4F11, CYP4A11 | PYGL 816/4885PLAU 1747/4885THRA 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.